Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY19 results · Oct–Dec 2018
Astec LifeSciences reported revenue from operations of ₹119.43 crore and net profit of ₹9.98 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.43 | — | — | 112.72 | +5.9% |
| Other income | 3.07 | — | — | 1.85 | +65.7% |
| Total income | 122.50 | — | — | 114.57 | +6.9% |
| Profit before tax | 15.33 | — | — | 17.91 | −14.4% |
| Net profit for the period | 9.98 | — | — | 11.57 | −13.8% |
| Attributable to shareholders of the company | 9.96 | — | — | 11.57 | −13.9% |
| EPS, basic (₹) | 5.10 | — | — | 5.92 | −13.9% |
| Net margin (%) | 8.4 | — | 10.3 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.43 | — | — | 112.72 | +5.9% |
| Other income | 3.03 | — | — | 1.85 | +63.7% |
| Total income | 122.46 | — | — | 114.57 | +6.9% |
| Profit before tax | 15.28 | — | — | 17.90 | −14.6% |
| Net profit for the period | 9.94 | — | — | 11.57 | −14.1% |
| EPS, basic (₹) | 5.09 | — | — | 5.92 | −14.0% |
| Net margin (%) | 8.3 | — | 10.3 |
Consolidated
- Filed with BSE
- 27 Jan 2019, 13:29 IST
- Board meeting
- 25 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2019, 13:29 IST
- Board meeting
- 25 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE